• Bendamustine glenmark

  Form: powder for preparation of concentrate for infusion solution

  Active substance	Dosage
  bendamustine hydrochloride monohydrate	25 mg/vial or 100 mg/vial

  ATC: L01AA09

• Bendamustine zentiva

  Form: powder for preparation of concentrate for infusion solution

  Active substance	Dosage
  bendamustine hydrochloride monohydrate	26.1 mg or 104.6 mg

  ATC: L01AA09

• Bortezomib glenmark

  Form: powder for preparation of injection solution

  Active substance	Dosage
  bortezomib	1 mg

  ATC: L01XG01

• Bortezomib glenmark

  Form: powder for preparation of injection solution

  Active substance	Dosage
  bortezomib	3.5 mg

  ATC: L01XG01

• Bortezomib medac

  Form: powder for preparation of injection solution

  Active substance	Dosage
  bortezomib	1 mg

  ATC: L01XX32

• Bortezomib medac

  Form: powder for preparation of injection solution

  Active substance	Dosage
  bortezomib	3.5 mg

  ATC: L01XX32

• Bortezomib zentiva

  Form: powder for preparation of injection solution

  Active substance	Dosage
  bortezomib	3.5 mg

  ATC: L01XX32

• Bortezomib zentiva

  Form: powder for preparation of injection solution

  Active substance	Dosage
  bortezomib	1 mg

  ATC: L01XX32

• Xaleba

  Form: tablets, film-coated

  Active substance	Dosage
  etoricoxib	30 mg

  ATC: M01AH05

• Xaleba

  Form: tablets, film-coated

  Active substance	Dosage
  etoricoxib	60 mg

  ATC: M01AH05

• Xaleba

  Form: tablets, film-coated

  Active substance	Dosage
  etoricoxib	90 mg

  ATC: M01AH05

• Xaleba

  Form: tablets, film-coated

  Active substance	Dosage
  etoricoxib	120 mg

  ATC: M01AH05